Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Evgeniya Ranneva

Evgeniya Ranneva

Skin Tech Pharma Group, Spain

Title: Medical device CE class III increases transcription of collagen type 1 and elastin genes in human skin fibroblast in vitro

Biography

Biography: Evgeniya Ranneva

Abstract

Mesotherapy/biorevitalization with hyaluronic acid (HA) is a treatment approach currently used for skin rejuvenation. Various products are available on the market and present a wide range of polycomponent formulations. Most of those formulations contain non cross linked hyaluronic acid in combination with a biorevitalization cocktail, formed by various amounts of vitamins, minerals, amino acids, nucleotides, coenzymes and antioxidants. Although ingredients are very similar in-between the different products, in vitro and clinical effects may vary substantially. There is a real need for better characterization of those products in terms of their action on human skin or in vitro skin model. In this study, we analyzed the effect of Medical device Class III based in HA on human skin fibroblast in vitro. Skin fibroblast viability and capacity to induce the production of key extracellular matrix was evaluated in presence of different concentration of RRS HA injectable. Viability was evaluated through MTT assay and key extracellular matrix genes collagen type 1 and elastin were quantified by quantitative PCR. Results demonstrated that the product could promote human skin fibroblast viability (+15%) and increased fibroblast gene expression of collagen type 1 gene a 9.7 fold and elastin a 14 fold time in vitro. Those results demonstrate that mesotherapy/biorevitalization products can effectively modulate human skin fibroblast at least in vitro.